Michael T. Hotchkin

Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis

Andrew P. Robinson, Joanne Zhongyan Zhang, Haley E. Titus et al. · Scientific Reports · 2020 · 85 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension

Steve Vucic, Parvathi Menon, William Huynh et al. · EClinicalMedicine · 2023 · 61 citations · Full text

Life Sciences, Neurology, Neuroscience +15

Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment

Steve Vucic, Toby A. Ferguson, Catherine Cummings et al. · Muscle & Nerve · 2021 · 55 citations

Life Sciences, Neurology, Neuroscience +17

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

Steve Vucic, Matthew C. Kiernan, Parvathi Menon et al. · BMJ Open · 2021 · 51 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials

Jimin Ren, Richard B. Dewey, Austin Rynders et al. · Journal of Nanobiotechnology · 2023 · 47 citations · Full text

Life Sciences, Neurology, Neuroscience +17